The Tobacco and Environmental Carcinogenesis Program was established as a result of the ACC Strategic Planning Process undertaken in 2007. At that time the Cancer Epidemiology and Risk Reduction Program was reconfigured and renamed to reflect our trans-disciplinary research efforts to address health issues related to tobacco, asbestos, and polycyclic hydrocarbons as environmental carcinogens and in tobaccorelated risk reduction. With Caryn Lerman taking on the role as Deputy Director ofthe Cancer Center, new leadership was required. Dr. Lerman was replaced by Steven Albelda, M.D. and Trevor Penning, Ph.D. Dr. Albelda is a leading expert in mesothelioma and thoracic malignancies, and Dr. Penning is an internationally renowned expert on polycyclic aromatic hydrocarbon carcinogenesis. These leaders are experienced, wellfunded investigators who are highly collaborative, as evidenced by their NIH POl, P50 and P30 grants. The TEC Program seeks to elucidate the relationships between cancer and exposure to known environmental carcinogens by studying the molecular mechanisms of carcinogenesis, developing and validating biomarkers of carcinogen exposure and response, determining genetic susceptibility to carcinogens, and improving strategies for the prevention, eariy detection and intervention of cancers with environmental causality. The initial focus ofthe program is on the etiology and prevention of tobacco- and asbestos-related cancers, particulariy lung cancer, head and neck cancer, and mesothelioma. The cancer prevention focus includes studies on why people smoke, smoking cessation, and hence the prevention of the cancer initiation process. This research theme provides a solid foundation on which to build studies that relate exposures to environmental carcinogens to cancers in other organ systems. These collaborative research efforts are facilitated by the Program Leaders, multiple research retreats, monthly program meetings and seminars, and Pilot Project grants. Members of this program utilize multiple Shared Resources, with extensive use of the Biostatistics, Biomedical Data Coordination, Genomics, and Proteomics Cores. Further, members of this program were actively involved in the development ofthe new Recruitment Outcomes Assessment Resource (ROAR) Shared Facility, which has been highly valuable for ongoing case-control and gene-environment interaction studies. Future plans are to expand the TEC program to include other cancers with environmental causality, increase strength in environmental epidemiology and introduce new research themes in cancer chemoprevention and lung cancer stem cells. The 16 members in the TEC Program have $7,732,268 in research funding (Annual Direct Costs) of which $7,392,900 is peer-reviewed and $3,739,865 is NCI-funded. Among the many multi-investigator grants are the Center for Interdisciplinary Research on Nicotine Addiction (which has research themes in the molecular and behavioral mechanisms of smoking cessation) and the Center of Excellence in Environmental Toxicology (which has research themes in lung and airway disease, oxidative stress and gene-environment interactions). Members have published 317 cancer-related articles, with 30% being intra-programmatic and 26% being inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593261
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$117,845
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571
Anton, Lauren; Sierra, Luz-Jeannette; DeVine, Ann et al. (2018) Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Lactobacillus crispatus Contributes to Cervical Health. Front Microbiol 9:2181
Williams, Austin D; Reyes, Sylvia A; Arlow, Renee L et al. (2018) Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged Ann Surg Oncol 25:2875-2883
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5

Showing the most recent 10 out of 1047 publications